Long-acting microspheres of Human Chorionic Gonadotropin hormone: In-vitro and in-vivo evaluation.

Human Chorionic Gonadotropin (hCG) hormone is used to cause ovulation, treat infertility in women, and increase sperm count in men. Conventional hCG solution formulations require multiple administration of hCG per week and cause patient noncompliance. The long-acting PLGA depot microspheres (MS) approach with hCG can improve patient compliance, increase the efficacy of hCG with a lower total dose and improve quality of life. Therefore, hCG was encapsulated by a modified double emulsion solvent evaporation technique within PLGA MS by high-speed homogenizer and industrially scalable in-line homogenizer, respectively. MS was characterized for particle size, encapsulation efficiency (EE), surface morphology, and in-vitro release. The spherical, dense, non-porous microspheres were obtained with a size of 58.88 ± 0.18 µm. Microspheres showed high EE (77.4% ± 5.9%) with low initial burst release (12.82% ± 2.07%). Circular Dichroism and SDS-PAGE analysis indicated good stability and structural integrity of hCG in the microspheres. Its bioactivity was proven further by a bioassay study in immature Wistar rats. Pharmacokinetic analysis showed that the hCG PLGA MS maintained serum hCG concentration up to 13 days compared to multiple injections of a marketed conventional parenteral injectable formulation of hCG. Thus, it can be ascertained that the hCG PLGA MS may have great potential for clinical use in long-term therapy. Copyright © 2021 Elsevier B.V. All rights reserved.

Citation

Manoj A Pawar, Lalitkumar K Vora, Prasad Kompella, Venkata Kishan Pokuri, Pradeep R Vavia. Long-acting microspheres of Human Chorionic Gonadotropin hormone: In-vitro and in-vivo evaluation. International journal of pharmaceutics. 2022 Jan 05;611:121312

Mesh Tags

Substances

PMID: 34822964

search → result